Waisbourd Michael, Katz L Jay
Wills Eye Hospital, Glaucoma Research Centre, Philadelphia, Pa..
Wills Eye Hospital, Glaucoma Research Centre, Philadelphia, Pa.
Can J Ophthalmol. 2014 Dec;49(6):519-22. doi: 10.1016/j.jcjo.2014.10.003.
Poor adherence with glaucoma medications has been well documented. There remains a significant unmet need for a relatively safe intraocular pressure (IOP)-lowering procedure that minimizes or eliminates patient participation, and thus reduce the incidence of treatment failures attributable to nonadherence. Selective laser trabeculoplasty (SLT) offers several advantages: It effectively reduces IOP in most patients with open-angle glaucoma, it is cost-effective compared with eye drops, it can be repeated if needed, and it eliminates the issue of adherence to medications when used as an initial treatment. This article reviews the evidence supporting the use of SLT as a first-line therapy in glaucoma.
青光眼药物治疗依从性差已有充分记录。对于一种相对安全的降低眼压（IOP）的手术，仍存在重大未满足需求，该手术可将患者参与度降至最低或消除，从而降低因不依从导致的治疗失败发生率。选择性激光小梁成形术（SLT）具有多个优点：它能有效降低大多数开角型青光眼患者的眼压，与滴眼液相比具有成本效益，如有需要可重复进行，并且作为初始治疗使用时可消除药物依从性问题。本文综述了支持将SLT用作青光眼一线治疗的证据。
